Clinical Trials

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

The purpose of this study is to:

1. Assess outcome differences in two groups of pediatric patients with chronic pain.

2. Review the perceived effectiveness and clinical utility of PGx testing on medical decision making in the management of children with chronic pain by discussing differences in pre and post-PGx testing plan of care recommendations.

The purpose of this study is to investigate understanding, retention, concerns, and expectations of individuals engaged in the process of utilizing pharmacogenomic testing as a clinical tool.

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing in established patients with liver disease seen in the Division of Gastroenterology/Hepatology, in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

The purpose of this study is to learn more about how individual women metabolize and respond to specific medications such as Naproxen and other NSAIDS. The way individuals metabolize NSAIDS may have a relationship to the effectiveness of Naproxen when used for treatment of heavy menstrual bleeding.

The purpose of this study is to:

1. To evaluate whether the genotypic and phenotypic results for a single subject are the same among companies offering pharmacogenomics testing.

2. To evaluate the consistency among company generated lists of medications stratified into groups regarding usage for a single subject (i.e., “use as directed,” “use with caution,” or “use with increased caution and with more frequent monitoring”).

The primary aim is to assess current pharmacogenomics education within nurse anesthesia programs.

A secondary aim is to provide educational recommendations on pharmacogenomics and its implications in anesthesia.

The purpose of this study is to test whether pharmacogenetics in psychiatric patients with polypharmacy can identify increased medication adverse effects and improve outcomes.

The purpose of this study is to learn more about how individuals break down and process their medications based on their genes.

The aim of this study is to better understand providers’ attitudes, perceptions and knowledge of pharmacogenomics and to examine the impact of experiential education with providers.  

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for surgical ovarian cancer patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of opioid medications.

The purpose of this study is to:

1. To evaluate the pharmacogenomic profile (PGx) by genotyping 22 genes, including the CYP2D6 genotype, in patients with functional GI disorders.
2. To assess the impact of PGx testing on prescriber patterns in this practice.
3. To explore the impact of PGx testing on patient outcomes after an assessment in this practice.

This study will use a 22 gene pharmacogenomics panel on 30 children with persistent Gastroesophageal Reflux Disease (GERD) who have not responded to therapy.

The purpose of this study is to look at the use of pharmacogenomic data in the perioperative period to guide drug therapy in patients undergoing total knee arthroscopy.

The purpose of this research study is to:

• Find out whether there are any DNA (genetic) changes and mutations that put you at risk of developing this skin reaction and use that information to predict the side effect on patients with similar results in the future.

• Help us better manage the hand-foot skin reaction if it develops by recommending the appropriate treatment

The overall goals of this pilot study are to: (1) describe pharmacogenomics (PGx) testing results and identify PGx variants that may inform treatment regimens and symptom management in cardiac surgical patients with an ICU stay, and (2) describe cardiac critical care team members’ awareness and attitudes towards the applications of pharmacogenomics testing results for their practice before and after completion of a PGx education module.
 

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications

The purpose of this study is to:

• Demonstrate pharmacogenetic variability in the Mayo Clinic Florida lung transplant population.
• Describe patterns in tacrolimus levels in the context of pharmacogenomic profiles
• Use pharmacogenomic data to establish a need for therapeutic drug monitoring in selected other drugs
• Use pharmacogenomic data, in combination with knowledge of drug interactions, to establish sensitivity to tacrolimus dose changes

This research is being done to better understand how genetic information related to drug dosing and use can affect medical care of patients.

This study is asking to allow access to stored blood sample in the Mayo Clinic Biobank (IRB#08-007049) so researchers can study DNA to find out if genetic variants that play a role in how the body responds to certain drugs, primarily prescription drugs. In this study, we are interested in genetic variants that may affect whether some people:

• need a lower or higher dose of a drug

• are at an increased risk of side effects to a ...

The goal of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.